Hiperhomocisteinemia y preeclampsia | Progresos de Obstetricia y Ginecología

Información del artículo

Resumen

Objetivo

Comparar las concentraciones plasmáticas de homocisteína en gestantes con preeclampsia con respecto a un grupo control de gestantes sanas durante el tercer trimestre de gestación, así como determinar la prevalencia de hiperhomocisteinemia entre ambos grupos

Sujetos y métodos

Estudio transversal de 100 gestantes durante el tercer trimestre de gestación (50 con preeclampsia y 50 gestantes sanas) en el Servicio de Obstetricia del Hopital La Paz entre enero y diciembre de 1999

Resultados

Las concentraciones de homocisteína plasmática están significativamente elevadas en las pacientes con preeclampsia con respecto a las gestantes normales (media ± desviación estándar [DE], 12,1 ± 4,2; intervalo de confianza [IC] del 95%, 11,7–12,9 frente a 5,9 ± 2,4; IC del 95%, 5,1–7,4 μmol/l; p = 0,01). La prevalencia de hiperhomocisteinemia (homocisteína > 8,3 μmol/l) es mayor en gestantes con preeclampsia respecto al grupo control (el 78 frente al 18%; p = 0,03)

Conclusiones

Las concentraciones plasmáticas de homocisteína están elevadas significativamente en gestantes con preeclampsia en comparación con gestantes sanas durante el tercer trimestre de gestación. La prevalencia de hiperhomocisteinemia es significativamente mayor en pacientes con preeclampsia respecto al grupo control

Palabras clave:

Homocisteína

Hiperhomocisteinemia

Preeclampsia

Gestación

Summary

Objective

To compare plasma concentrations of homocysteine in pregnant women with preeclampsia with those in a group of healthy pregnant women during the third trimester of pregnancy and to determine the prevalence of hyperhomocystinemia in both groups

Subjects and methods

Cross sectional study of 100 pregnant women during the third trimester of pregnancy (50 with preeclampsia and 50 with normal pregnancy) in the Department of Obstetrics of Hospital La Paz between January and December 1999

Results

Plasma concentrations of homocysteine were significantly higher in patients with preeclampsia than in non-preeclamptic women (mean ± SD: 12.1 ± 4.2; 95% CI: 11.7–12.9 vs 5.9 ± 2.4; 95% CI: 5.1–7.4 μmol/l; p = 0.01). The prevalence of hyperhomocystinemia (homocysteine > 8.3 μmol/l) was also higher in preeclamptic women than in non-preeclamptic women (78% vs 18%; p = 0.03)

Conclusions

Plasma concentrations of homocysteine were significantly higher in pregnant women with preeclampsia than in non-preeclamptic pregnant women in the third trimester of pregnancy. The prevalence of hyperhomocystinemia was significantly higher in preeclamptic pregnant women than in non-preeclamptic women

Key words:

Homocysteine

Hyperhomocystinemia

Preeclampsia

Pregnancy

El Texto completo está disponible en PDF

Bibliografía

[1.]

Gupo de Consenso sobre Estados Hipertensivos del Embarazo.

Documentos de Consenso de la Sociedad Española de Ginecolgía y Obstetricia, 3 (1998), pp. 45-78

[2.]

C.J. Boushey, S.A.A. Boresford, G.S. Omenn, A.G. Motulsky.

A quantitative assesment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

Jama, 274 (1995), pp. 1049-1057

Medline

[3.]

H. Refsum, P.M. Veland, O. Nygard, S.E. Vollset.

Homocysteine and cardiovascular disease.

Ann Rev Med, 49 (1998), pp. 31-61

http://dx.doi.org/10.1146/annurev.med.49.1.31 | Medline

[4.]

G.S. Ommen, S.A.A. Baresfold, A.G. Motulsky.

Preventing coronary heart disease: B vitamins and homocysteine.

Circulation, 97 (1998), pp. 421-424

Medline

[5.]

N.J. Wald, H.C. Watt, M.R. Law, D.G. Weir, J. McPartlin, J.M. Scott.

Homocysteine and ischemic heart disease.

Arch Int Med, 158 (1998), pp. 862-867

[6.]

A. Rajkovic, P. Catalano, R. Malinow.

Elevated homocysteine levels with preeclampsia.

Obstet Gynecol, 90 (1997), pp. 168-171

http://dx.doi.org/10.1016/S0029-7844(97)00223-8 | Medline

[7.]

S. Sánchez, C. Zhang, M. Rene-Malinow, S. Ware-Jauregui, G. Larrabure, M.A. Williams.

Plasma folate, vitamin B (12), and homocysteine concentrations in preeclamptic and normotensive Peruvian women.

Am J Epidemiol, 153 (2001), pp. 474-480

Medline

[8.]

A.M. Lachmeijer, R. Argrimsson, E.J. Bastiaans, G. Pals, L.P. ten Kate, J.I. de Vries, et al.

Mutations in the gene for methylenetetrahydrofolate reductase, homocysteine levels, and vitamin status in women with a history of preeclampsia.

Am J Obstet Gynecol, 184 (2001), pp. 394-402

Medline

[9.]

J.G. Ray, C.A. Laskin.

Folic acid and homocysteine metabolic defects and the risk of placental abruption, preeclampsia and spontaneous pregnancy loss: A systematic review.

Placenta, 20 (1999), pp. 519-529

http://dx.doi.org/10.1053/plac.1999.0417 | Medline

[10.]

M.T. Raijmakers, P.L. Zusterzeel, E.M. Roes, E.A. Steegers, T.P. Mulder, W.H. Peters.

Oxidized and free whole blood thiol in preeclampsia.

Obstet Gynecol, 97 (2001), pp. 272-276

Medline

[11.]

J. Perales, L.E. Martínez de Villarreal, H. Triana, D. Saldivar, H. Barrera, A. Rojas, et al.

Niveles de ácido fólico, homocisteína y polimorfismo de la enzima metilentetrahidrofolatorreductasa (MTHFR) en pacientes con preeclampsia severa y eclampsia.

Ginecol Obstet Mex, 1 (2001), pp. 696-711

[12.]

M.T. Raijmakers, P.L. Zusterzeel, E.A. Steegers, M.P. Hectors, P.N. Demacker, W.H. Peters.

Plasma thiols status in preeclampsia.

Obstet Gynecol, 95 (2000), pp. 180-184

Medline

[13.]

J. Wang, B.J. Trudinger, N. Duarte, D.E. Wilcken, X.L. Wang.

Elevated circulating homocysteine levels in placental vascular disease and associated preeclampsia.

Bjog, 107 (2000), pp. 935-938

[14.]

H. Laivuori, R. Kaaja, U. Turpeinen, L. Viinikka, O. Ylikorkala.

Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia.

Obstet Gynecol, 93 (1999), pp. 489-493

Medline

[15.]

R.W. Powers, R.W. Evans, A.K. Majors, J.I. Ojimba, R.B. Ness, W.R. Crombleholme, et al.

Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation.

Am J Obstet Gynecol, 179 (1998), pp. 1605-1611

Medline

[16.]

M.T. Raijmakers, P.L. Zusterzeel, E.A. Steegers, W.H. Peters.

Hyperhomocisteinaemia: a risk factor for preeclampsia?.

Eur J Obstet Gynecol Reprod Biol, 95 (2001), pp. 226-228

Medline

[17.]

T. Kaiser, S.P. Brennecke, E.K. Moses.

C677T methylenetetrahydrofolate reductase polymorphism is not a risk factor for preeclampsia/eclampsia among Australian women.

Hum Hered, 51 (2001), pp. 20-22

http://dx.doi.org/22954 | Medline

[18.]

K. Mayerhofer, L. Hefler, H. Zeisler, C. Tempfer, K. Bodner, S. Stockle-Ipsiroglu, et al.

Serum homocysteine levels in women with preeclampsia.

Wien Klin Wochenschr, 112 (2000), pp. 271-275

Medline

[19.]

A. Anderson, B. Hultberg, L. Brattstrom, A. Isaksson.

Decreased serum homocysteine in pregnancy.

Eur J Clin Chem Clin Biochem, 30 (1992), pp. 377-379

Medline

[20.]

R. Hietala, U. Turpeinen, T. Laatikainen.

Serum homocysteine at 16 weeks and subsequent preeclampsia.

Obstet Gynecol, 97 (2001), pp. 527-529

Medline

[21.]

B.B. Hogg, T. Tamura, K.E. Johnson, M.B. Dubard, R.L. Goldenberg.

Second-trimester plasma homocysteine levels and pregnancy induced hypertension.

Am J Obstet Gynecol, 183 (2000), pp. 805-809

http://dx.doi.org/10.1067/mob.2000.109044 | Medline

[22.]

T.K. Sorensen, M.R. Malinow, M.A. Williams, I.B. King, D.A. Luthy.

Elevated second-trimester serum homocysteine levels and subsequent risk of preeclampsia.

Gynecol Obstet Invest, 48 (1999), pp. 98-103

http://dx.doi.org/10148 | Medline

[23.]

S. Kang, P.W.K. Wong, J. Zhou, H. Cook.

Total homocysteine in plasma and amniotic fluid of pregnant woman.

Metabolism, 35 (1986), pp. 889-891

Medline

[24.]

C. Fernández-Miranda, J.L. Aranda, P. Gómez González, P. Díaz-Rubio, J. Estenoz, A. Gómez.

La hiperhomocisteinemia es frecuente en pacientes con enfermedad coronaria. Estudio de 202 enfermos.

Med Clin, 113 (1999), pp. 407-410

Indexada en:

Síguenos:

Indexada en:

Síguenos:

Suscríbase a la newsletter